Comorbidities, Gender, and Race in the Severity of COVID-19
DOI:
https://doi.org/10.14738/bjhr.1206.19738Keywords:
Comorbidities, Gender, Race in the Severity of COVID-19Abstract
Objective: COVID-19 pandemic claimed a lot of lives. Comorbidities have been suggested to drive the number of patients who suffered from COVID-19. This study was conducted retrospectively to examine how comorbidities like diabetes, hypertension, and factors like vaccination, race and gender impacted COVID-19 in patients admitted to the hospital (in-patient services) with a COVID-19 diagnosis. Method: A retrospective cohort study of 17,624 adult patients diagnosed with COVID-19 and admitted to in-patient services at Ochsner Health, between March 1, 2020 and March 31, 2022 was conducted. All data, including demographics, comorbidities, laboratory results, COVID-19 vaccination status, and severity of disease were collected from the electronic health record and analyzed. Result: In the unadjusted analysis, diabetes and hypertension were statistically significant predictors of major/extreme SOI (p < 0.0001) and ROM (p < 0.0001). Age and vaccination status were significant (p < 0.0001), but the strength of association was weak: as age increases, severity of illness (SOI) increases (RR=1.00(1.00-1.00)). Length of hospital stay was significantly longer for patients with diabetes after controlling for age and prior vaccination status (p < 0.0001). This study also shows that patients with diabetes or hypertension comorbidities were more likely to be vaccinated prior to admission than those without the comorbidity. Conclusion: Our study showed that patients with diabetes or hypertension comorbidities were more likely to be vaccinated prior to admission than those without the comorbidity. However, having these diagnoses may worsen the outcome of COVID-19 infection. Diagnosis with prior diabetes or hypertension was marginally associated with major or extreme severity of illness [RR(95% CI)= 1.02(1.01-1.03) and RR(95% CI)= 1.01(1.01-1.02)] and risk of mortality [RR(95% CI)= 1.05(1.04-1.07) and RR(95% CI)= 1.03(1.02-1.04)] compared to minor or moderate risk.
References
Corona Virus Disease, DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 132e, 12th Edition
(Public Health December 6, 2024). CDC
Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020:200274. https://doi.org/10.1148/radiol.2020200274.
Friedman J, Liu P, Troeger CE, et al. Predictive performance of international COVID-19 mortality forecasting models. Nat Commun. 2021;12 [PMC free article] [PubMed] [Google Scholar]
Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. Published online October 5, 2020. doi:10.1001/jama.2020.19719. (Public Health December).
Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection – United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(40):1450-1456. Published 2020 Oct 9. doi:10.15585/mmwr.mm6940e1
The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020: Kathleen Dooling 1,✉, Mona Marin 1, Megan Wallace 1,2, Nancy McClung 1, Mary Chamberland 1,3, Grace M Lee 4, H Keipp Talbot 5, José R Romero 6, Beth P Bell 7, Sara E Oliver 1 URL: http://dx.doi.org/10.14738/bjhr.1206.19738. 201
The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths: Teresa K Yamana 1,* Marta Galanti 1, Sen Pei 1, Manuela Di Fusco 2, Frederick J Angulo 3, Mary M Moran 3, Farid Khan 3, David L Swerdlow 3, Jeffrey Shaman 1,4
Leung JM, Yang CX, Tam A et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. doi: 10.1183/13993003.00688-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
Farsalinos K, Barbouni A, Poulas K et al. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320935765. doi: 10.1177/2040622320935765. [DOI] [PMC free
The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths: Teresa K Yamana 1,* Marta Galanti 1, Sen Pei 1, Manuela Di Fusco 2, Frederick J Angulo 3, Mary M Moran 3, Farid Khan 3, David L Swerdlow 3, Jeffrey Shaman Therapeutics and COVID-19: living guideline, August 20251,4,*
Leo Lopez III, MD, MHS1; Louis H. Hart III, MD1; Mitchell H. Katz, MD1. Racial and Ethnic Health Disparities Related to COVID-19. JAMA Vol. 325, No. 8.
NIH Releases Final Version of COVID-19 Treatment Guidelines, 2024 National Institutes of Health {NIH} guidelines.
World Health Organization: Therapeutics and COVID-19: living guideline, August 2025
October 2025 Infectious Diseases Society of America {IDSA} update. All hospitalized patients with confirmed/suspected COVID-19.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patience O Obih, Ph.D., Elizabeth Howard, Ph.D., Ijeoma Innocent-Itua, MD., Susan Olet, Ph.D.

This work is licensed under a Creative Commons Attribution 4.0 International License.